Krystal Biotech/$KRYS
1D1W1MYTD1Y5YMAX
Capital at risk
About Krystal Biotech
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
- Ticker
- $KRYS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 295
- Headquarters
- Pittsburgh, United States
- Website
- www.krystalbio.com
Krystal Biotech Metrics
BasicAdvanced
$10B
44.10
$7.97
0.54
-
Price and volume
Market cap
$10B
Beta
0.54
52-week high
$382.54
52-week low
$136.73
Average daily volume
283K
Financial strength
Current ratio
8.318
Quick ratio
7.726
Long term debt to equity
0.518
Total debt to equity
0.651
Profitability
EBITDA (TTM)
199.293
Gross margin (TTM)
94.64%
Net profit margin (TTM)
54.82%
Operating margin (TTM)
44.89%
Effective tax rate (TTM)
-6.55%
Revenue per employee (TTM)
$1,490,000
Management effectiveness
Return on assets (TTM)
9.37%
Return on equity (TTM)
20.12%
Valuation
Price to earnings (TTM)
44.097
Price to revenue (TTM)
23.299
Price to book
7.65
Price to tangible book (TTM)
7.65
Price to free cash flow (TTM)
39.812
Free cash flow yield (TTM)
2.51%
Free cash flow per share (TTM)
8.823
Growth
Revenue change (TTM)
22.63%
Earnings per share change (TTM)
62.40%
3-year earnings per share growth (CAGR)
13.71%
What the Analysts think about Krystal Biotech
Analyst ratings (Buy, Hold, Sell) for Krystal Biotech stock.
Analyst projections of the future price of Krystal Biotech stock.
Bulls say / Bears say
Global VYJUVEK net product revenue grew 24% year-over-year to $119.2 million in Q2 2026, driven by launches in Europe and Japan (Form 8-K)
Krystal secured over 730 reimbursement approvals and expanded its VYJUVEK prescriber base to more than 640 unique prescribers by end-June 2026, enhancing patient access (GlobeNewswire)
The company closed Q2 2026 with $1.1 billion in cash and investments, underpinning its ability to fund operations and pipeline development (GlobeNewswire)
International revenue growth was partially offset by a reduction in United States VYJUVEK sales in Q2 2026, indicating domestic market pressure (Form 10-Q)
Ongoing pricing discussions with Italian and Spanish reimbursement authorities, as well as unresolved negotiations in Germany and France, could delay planned European launches beyond H2 2026 (IR Release)
With VYJUVEK representing the vast majority of sales, Krystal remains exposed to single-product risk ahead of multiple registrational readouts planned in H2 2026 (Form 8-K)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
Krystal Biotech Financial Performance
Revenues and expenses
Krystal Biotech Earnings Performance
Company profitability
Upcoming events
No upcoming events
Krystal Biotech News
AllArticlesVideos
Funds containing Krystal Biotech
AllUSDGBPEUR
Fund name | Fund size | $KRYS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.75% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.75% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.29% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.26% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.26% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.